Laprituximab emtansine

Names

[ Name ]:
Laprituximab emtansine

Biological Activity

[Description]:

Laprituximab emtansine (IMGN-289) is an immunotoxin targeting HER1. Laprituximab emtansine is an EGFR antibody-drug conjugate (ADC) consisting of the J2898A antibody, DM1 (anti-microtubule agent) and the SMCC thioether linker. Laprituximab emtansine can be used for cancer research[1][2][3].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> EGFR

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

[Target]

HER1

[In Vitro]

Laprituximab emtansine 显示出对 HNSCC 细胞系的抗克隆形成和抗增殖活性，IC50s 为 0.003 nM-1.74 nM[3]。 Laprituximab emtansine 对 NSCLC 细胞系和 EGFR 突变 HCC827 细胞系具有细胞毒性[2]。 Cell Viability Assay[3] Cell Line: PBMCs from humans, rhesus and cynomolgus animals Concentration: 0-1 μg/mL approximately Incubation Time: 3 days Result: Inhibited rCD154-induced proliferation of PBMCs with IC50s of 0.02, 0.03, and 0.01 μg/mL, respectively.

[In Vivo]

Laprituximab emtansine (1-5 mg/kg，静脉注射) 在 EGFR 阳性 SCCHN 异种移植模型中导致肿瘤消退[4]。 Animal Model: EGFR-positive SCCHN xenograft model[4] Dosage: 1, 2.5, 5 mg/kg Administration: i.v. Result: Resulted tumor regression with a minimally efficacious dose of 1 mg/kg, and highly active at 2.5 and 5 mg/kg.

[References]

[1]. Moradi-Kalbolandi S, et al. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. J Pharm Pharmacol. 2018 Jul;70(7):841-854.

[2]. Yulius Y. et al. Abstract 4513: IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors. Cancer Res 1 October 2014; 74 (19_Supplement): 4513.

[3]. Hyunseok Kang, et al. Antitumor effect of IMGN289, an anti-EGFR antibody-drug conjugate (ADC), in preclinical models of head and neck squamous cell carcinomas (HNSCC). Journal of Clinical Oncology. 2014. 32, no. 15_suppl.

[4]. Jose F. Ponte, et al. Abstract 5483: Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck. Cancer Res (2013) 73 (8_Supplement): 5483.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.